- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| Di | RACURA ONCOLOGY LTD: Racura Oncology Research Symposium Sydney | - | ASX | ||
| Mo | RACURA ONCOLOGY LTD: Racura Investor Briefing Hong Kong and Singapore | - | ASX | ||
| 27.02. | RACURA ONCOLOGY LTD: Appendix 4D & Half-Year Financial Statements | 1 | ASX | ||
| 26.02. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 19.02. | RACURA ONCOLOGY LTD: Appendix 3Y - Dr Daniel Tillett | - | ASX | ||
| 19.02. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | 1 | ASX | ||
| RACURA ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 16.02. | RACURA ONCOLOGY LTD: Appendix 3Y - Dr Daniel Tillett | 1 | ASX | ||
| 12.02. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | 1 | ASX | ||
| 10.02. | RACURA ONCOLOGY LTD: Racura Develops Novel Cardioprotection Blood Test | 1 | ASX | ||
| 05.02. | RACURA ONCOLOGY LTD: Notification of buy-back - RAC | - | ASX | ||
| 05.02. | RACURA ONCOLOGY LTD: Capital Structure Update | - | ASX | ||
| 05.02. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | 1 | ASX | ||
| 29.01. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | 2 | ASX | ||
| 28.01. | RACURA ONCOLOGY LTD: December 2025 Quarterly Activity Report and Appendix 4C | - | ASX | ||
| 22.01. | RACURA ONCOLOGY LTD: Appendix 3Y - Dr Daniel Tillett | 3 | ASX | ||
| 22.01. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | 2 | ASX | ||
| 15.01. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | 1 | ASX | ||
| 13.01. | RACURA ONCOLOGY LTD: Racura Oncology Emory University Collaboration | - | ASX | ||
| 08.01. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | 1 | ASX |
1 2 3 4 5 Weiter >>
91 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TANGO THERAPEUTICS | 16,820 | 0,00 % | Erasca, Inc.: Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat | ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO... ► Artikel lesen | |
| ARCELLX | 114,36 | +0,09 % | Weekly Buzz: MGNX's LINNET Trial On Hold; Eton Pharmaceuticals, ALUR Get FDA Nod; GILD Snaps Up ACLX | FOSTER CITY (dpa-AFX) - This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results... ► Artikel lesen | |
| ERASCA | 15,560 | +2,91 % | Clear Street raises Erasca stock price target on combination trial deal | ||
| TYRA BIOSCIENCES | 34,550 | -2,07 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| CG ONCOLOGY | 60,35 | -1,87 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 70,96 | -1,79 % | RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook | ||
| ADMA BIOLOGICS | 15,700 | -5,11 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| BEAM THERAPEUTICS | 25,520 | 0,00 % | Beam Therapeutics Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 37,450 | +1,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 28,510 | -0,31 % | UBS cuts Harmony Biosciences stock price target on earlier Wakix generic entry | ||
| MINERALYS THERAPEUTICS | 26,700 | -7,29 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| IMMUNOME | 20,950 | 0,00 % | Immunome: Q4 Earnings Insights | ||
| VERA THERAPEUTICS | 38,850 | -2,02 % | Vera Therapeutics adds Christopher Hite to board of directors | ||
| DISC MEDICINE | 60,31 | -1,20 % | Disc Medicine undergoes restructuring plan; slashes 20% of workforce | ||
| ALUMIS | 27,660 | -4,17 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen |
RACURA ONCOLOGY LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,32 % bei einem Aktienkurs von 1,490 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RACURA ONCOLOGY LTD finden Sie auf Wallstreet Online.